

A photograph of two women in teal Ovarian Cancer Action gear. The woman on the left is wearing a teal t-shirt with the Ovarian Cancer Action logo and is holding a silver medal. The woman on the right is wearing a teal hoodie and is also holding a silver medal. They are both smiling and looking at the camera. In the background, there is a teal banner with the word 'can' and other people at what appears to be a triathlon event.

**Join us.
Fight with us.
Act now.**

Annual report & financial statements,
year ended 31 March 2018

A company limited by guarantee, registered in
England and Wales 5403443 Registered charity
numbers 1109743 (England and Wales) and SC
043478 (Scotland)





CAMPAINING FOR
CHANGE IN PARLIAMENT



WE FUND RESEARCH
TO SAVE LIVES

Annual Report Contents.

4	About us	22	Structure, governance and management	44	Thank you
6	Chair's report				
8	Director's report	23	Financial review		
10	Achievements and goals	24	Statement of directors' responsibilities		
12	Our top ten highlights	25	Reference and administrative details		
20	The year in numbers	26	Auditor's report		
		30	Statement of financial activities		
		31	Balance sheet		
		32	Statement of cash flows		
		33	Notes to the financial statements		

About Us

Who we are and why we exist

Ovarian Cancer Action is the UK's ovarian cancer research charity. We fund critical research, raise much-needed awareness, and campaign to stop women dying of the UK's deadliest gynaecological disease. **A disease that kills 4,100 women in the UK each year – more than the other gynaecological cancers combined.**

A small team with big ambitions

Our charity was founded to advance research and protect future generations of women from ovarian cancer. We're a small team with big ambitions and a strong belief in the power of collaborative action. We're here to unite scientists, campaigners, and patient voices and lead a nationwide movement that will overcome the disease once and for all. It's time to give women facing ovarian cancer a better future.

What an ovarian cancer diagnosis means today

7,400 new cases of ovarian cancer are diagnosed each year in the UK and there are 25,000 women living with the disease. These women face a complicated and often deadly disease that remains underfunded and frustratingly overlooked. This is reflected by the UK's survival rates, which have remained stagnant for years and are some of the worst in Europe.

Currently, a woman diagnosed with ovarian cancer in the UK has a 46% chance of living a further five years. This drops even further to 19% if she's diagnosed late, which happens all too frequently as the symptoms are notoriously vague and there is no national screening programme. Once diagnosed, there are limited treatment options available and the quality and accessibility of these is a postcode lottery. Even when treatment is initially successful, many ovarian cancers become resistant to chemotherapy, a worrying reality considering the disease recurs in 70%-90% of women. It's clear that ovarian cancer poses a unique set of problems that require immediate attention and collective action.

The mission

We're dedicated to transforming the landscape of ovarian cancer by a powerful research-driven agenda that challenges the disease at every stage. Our mission may be tough but we have already made significant progress since our foundation more than a decade ago. It is inspiring to note that, thanks to sustained investment in research and awareness, breast cancer survival rates increased from 40% in 1970 to 87% today. With the right support our goal is to replicate this success.

Our vision is a world where no woman dies from ovarian cancer and if we are to achieve this we must take a strategic approach.

Our strategy

We fund research to save lives

Research is the only way to drastically improve ovarian cancer survival rates. That's why we commit up to 50% of our annual expenditure to both established and up-and-coming researchers whose work will help break this cancer.

We support a talented team of scientists and clinicians at the Ovarian Cancer Action Research Centre – the first centre in Europe dedicated solely to ovarian cancer research – the University of Oxford, and the University of Glasgow. Our researchers are working to solve the major problems women face across the ovarian cancer pathway – from screening and early detection, to treatment and recurrence.

Scientific research is a long-game that requires sustained investment and strategic planning. Our research strategy is shaped by our Scientific Advisory Board; a team of scientific and clinical experts who guide research investment decisions. They ensure the projects we fund are of an excellent standard and, most importantly, will benefit and transform the lives of women with ovarian cancer.



We set the international research agenda

Every four years Ovarian Cancer Action curates an international conference. The HHMT International Forum on Ovarian Cancer brings together the world's leading ovarian cancer scientists and clinicians who debate ways to drive progress in research. They set research priorities which shape our own scientific objectives and harmonise global efforts to cure ovarian cancer. The next conference will take place in 2019.

We raise awareness

Ovarian cancer awareness is dangerously low. And this is costing lives. Spreading the word about ovarian cancer – its signs,

symptoms and risk factors – is a crucial part of our work. We're here to empower women and educate doctors; to give each the knowledge and confidence they need to catch the disease quickly.

We campaign for change

Ovarian Cancer Action shines a spotlight on the issues that impact women with, or at risk of, ovarian cancer. We campaign across all four nations to create equal access to high quality information, treatment, and genetic testing to families at risk of hereditary ovarian cancer – something that could save 1,000 lives each year.

Chair's report

A year of progress

It is very difficult to pick out a particular highlight from last year as, with your support, Ovarian Cancer Action has achieved so much. From launching a policy paper in parliament to funding exciting new areas of research, I'm proud of the progress we continue to make.

Research remains at the forefront of our agenda and with our new programme comes a new Director of Research for the Ovarian Cancer Action Research Centre. We are delighted to welcome Professor Iain McNeish who has worked with OCA for more than ten years as the lead on BriTROC; a pioneering study of ovarian cancer samples from more than 500 women over time, to better understand the disease and why tumours often stop responding to chemotherapy. Our unique Research Centre was founded in 2005 and we have no doubt it will continue to grow and flourish under Professor McNeish's leadership.

We also made great strides in our cancer prevention efforts, launching our *Acting On BRCA* policy paper in Parliament and taking a trip to Number 11 Downing street to kick-off phase I of our Development Appeal – a bid to raise £2 million for Professor Ahmed's vital work at Oxford into developing a screening tool.

Professor Ahmed's work was the focus of our 'Stolen Moments' campaign for Ovarian Cancer Awareness Month in March, in which our incredible Voices shared their stories to highlight how, on average, 19 years are stolen from women with ovarian cancer in the UK. The campaign was featured in publications such as *The Times*, *Women's Health* and the *Huffington Post*, raising awareness of ovarian cancer with women across the UK.

Raising awareness and achieving early diagnosis are the key to reducing deaths from this disease but only research will win our fight and change the future.

Of course we can't do any of this alone, and we are very grateful for our inspirational supporters who have taken on sporting

challenges, hosted events and so much more to raise vital funds for OCA. This year they have walked 4,232 miles, pedalled the equivalent of nine times around the globe and raised a staggering £1,855,641 to fund our vital work.

This year has been particularly special for me as it is my last in the role of Chair. After 13 years I will be stepping down but I am delighted to have been asked to remain involved as an advisor and ambassador in the role of President. I will be succeeded in summer 2018 by our current Vice-Chair, Dr Wayne Phillips.

Since founding the charity in 2005 we have achieved an enormous amount, and I would like to say a special thank you to each and every one of our supporters, as well as our Voices, volunteers, Business Development Committee, and our fantastic board of trustees who generously give their time to guide our work.

Ovarian cancer is a complicated, challenging disease, and there is still much to be done. However I think this report highlights what we are up against and how, with your help, we are campaigning to ensure ovarian cancer gets the funding and attention that it deserves. The inspirational women affected by ovarian cancer are at the heart of everything we do and that is exactly why we will continue to give it our all.

Thank you for joining our fight.



Allyson Kaye
Chair of the Board
(Resigned 16th July 2018)



PROFESSOR AHMED
IN THE LAB AT THE
UNIVERSITY OF OXFORD

**“Only research
will win our
fight and
change the
future”**

Allyson Kaye, Chair



Director's report

Financial year 2017/18.

The directors of the charity for the purpose of the Companies Act, are pleased to present their report and accounts for the year ended 31 March 2018 which are also prepared to meet the requirements for a directors' report and accounts for Companies Act purpose.

The financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

Public benefit

The Charities Act 2011 requires all charities to meet the legal requirement that its aims are for the public benefit. The Charity Commission in its Charities and Public Benefit guidance states that there are two key principles to be met in order to show that an organisation's aims are for the public benefit: firstly, there must be an identifiable benefit or benefits and secondly, that the benefit must be to the public or a section of the public. The directors consider that they have complied with Section 17 of the Charities Act 2011 including the guidance 'public benefit: running a charity (PB2)'.

Pay policy for staff

The Chief Executive and the senior management team including the Public Affairs and Operations Manager, Senior Fundraising Manager, Research Fundraising Manager and Head of Communications comprise the key management personnel of the charity in charge of directing and controlling, running and operating the charity on a day to day basis. All Directors give of their time freely and no Directors received remuneration in the year. The pay of senior staff is reviewed annually and is normally increased in accordance with average earnings.

Fundraising Policy

The charity is registered with the Fundraising Regulator to which it contributes via the levy on fundraising charities. We adhere to the Fundraising Regulator's Code of Practice and to Charity Commission Guidelines. The charity works with third-party suppliers from time to time to carry out fundraising activities.

The charity ensures that it is in compliance with General Data Protection Regulation (GDPR), particularly in regard to the collection and processing of personal data for fundraising purposes. Our privacy policy covers how we use our donor's data and provides opportunities to opt out of contact and make a complaint at any time.

There have been no complaints nor any recorded failures to comply with the Fundraising Regulator in the last financial year or since the Fundraising regulator was introduced.

The charity has the following policies in place to ensure positive and appropriate supporter engagement:

- Working with third party suppliers policy;
- People in vulnerable circumstances policy;
- Gift acceptance and refusal policy;
- Privacy policy;
- Data protection policy;
- Complaints policy.



OCA CHIEF EXECUTIVE
KATHERINE TAYLOR



TEAM OCA AT THE
LONDON MARATHON

Achievements

This year we made exciting progress.

2017-2018

Research

Invest in translational scientific research at the Ovarian Cancer Action Research Centre	Done
Carry out the Ovarian Cancer Action Research Centre's second quinquennial review	Done
Publish our Research Strategy for the next 5 years of funding scientific research	In progress
Fund research into prevention and early diagnosis at the University of Oxford	Done
Support the nationwide BritROC consortium's study of genetic changes in ovarian cancer	Done
Launch the Ovarian Cancer Action Development Appeal	Done
Continue planning the 14th HHMT International Forum on Ovarian Cancer	In progress
Communicate the latest science in the field of ovarian cancer research as widely as possible	Done

Awareness

Carry out a strategic review of our awareness raising programme	In progress
Raise awareness of ovarian cancer and inherited risk with GPs and Health Care Practitioners	Done
Raise awareness of ovarian cancer and inherited risk with the general public	Done
Review our awareness materials and gain Information Standards accreditation	In progress
Produce new materials on living with ovarian cancer and end of life care	In progress
Develop and implement a wide reaching awareness campaign for Ovarian Cancer Awareness Month	Done
Train OCA Voices to deliver awareness talks around the UK	Done
Update our online BRCA hub and risk tool ensuring information is in line with the latest scientific developments	Done

Campaigning

Survey the BRCA community and publish a report on the current provision of genetic testing	Done
Campaign for a Wales-wide symptoms awareness programme	Done
Engage with political stakeholders following the General Election and EU exit negotiations	Done

Goals

Next year we will do even more.

Research

Continue planning the 14th HHMT International Forum on Ovarian Cancer.
Launch a programme of new grants at the Ovarian Cancer Action Research Centre and monitor their impact.
Launch the Ovarian Cancer Screening Appeal to fund new research into prevention and early diagnosis at the University of Oxford.
Launch a new open grant for an ovarian cancer immunotherapy research programme.
Develop and agree funding for new research partnerships to increase impact of our research spend.

Awareness

Develop and implement a wide reaching awareness campaign for ovarian cancer.
Launch hereditary cancer risk tool and implement an outreach campaign to the high risk communities.
Undertake strategic review of our awareness raising programme to maximise impact.

Campaigning

Campaign for an ovarian cancer clinical audit.
Develop and plan launch for a new campaign to improve survival rates in ovarian cancer.

Governance

Recruit new membership to our Board of Trustees.
Develop and implement a long term strategic review.
Create a roadmap for digital transformation.

100

From launching an appeal to fund the world's first ovarian cancer screening tool, to our fabulous supporters raising funds and awareness across the country, it's been a year with many highlights. Here are our top ten.

1 Stolen Moments

Almost 20 years are stolen from a woman who dies of ovarian cancer in the UK. Within these decades are years of missed anniversaries, birthdays, weddings and graduations. In March we unveiled Stolen Moments: a storytelling campaign that brought to light the devastating consequences of ovarian cancer on women and their families.

United Voices


The campaign was grounded in the stories of 20 Voices; men and women whose lives had been changed by an ovarian cancer diagnosis. Throughout March, Ovarian Cancer Awareness Month,

they shared the moments they had missed and the loved ones they had lost to the disease. Their stories highlighted the human cost of ovarian cancer and helped us present a solution to late diagnosis.

Prevention is better than cure

We made a direct appeal to the public: help us raise £1 million to fund an ovarian cancer screening tool and protect future generations of women. And the result was brilliant! People across the UK donated, spread the word on social media, ordered awareness materials, organised Walk In Her Name and Box2Beat Cancer events, and more.

Stolen Moments was a powerful coming together of voices to inspire action. We hope this action will drive ground-breaking research in the coming years.



“My diagnosis has taught me to appreciate the world's beauty”

Florence Wilks, OCA Voice

FLORENCE WILKS,
ONE OF THE FACES
OF OUR CAMPAIGN

LAURA MOSES
TAKING PART IN
OUR FILM TO
RAISE AWARENESS



WALK IN HER NAME 2018



ALICIA WITH VAUGHAN GETHIN AM



ALISON'S WALK WAS ATTENDED BY MORE THAN 200 PEOPLE

2

Wales

Ovarian cancer is the UK's deadliest gynaecological cancer, but nowhere is it deadlier than in Wales. In 2016 we appointed Alicia Roberts as our first Wales Regional Officer, to better the lives of women facing the disease.

Two years on, Wales is now a collaborative hub of campaigning and awareness activity. Here are some of the ways we stepped up our efforts against ovarian cancer.

National awareness

Determined to arm women across Wales with the information they need to spot cancer, we have:

- Produced bilingual Welsh information materials with the help of Voice Sharon Jones
- Displayed digital information in GP surgeries across Powys and Cwm Taf
- Run awareness training sessions in Monmouthshire, Cardiff and Carmarthenshire
- Given 45 awareness talks
- Met with lead cancer nurses from hospitals across North Wales
- Flown the flag for Welsh cancer patients at national health conferences

All in all, Alicia met more than 2,000 people throughout the year in her mission to raise national awareness.

Ovarian Cancer Action has also used its position in the Wales Cancer Alliance to open conversations

about better symptoms awareness amongst medical professionals with the Cancer Implementation Group.

Gaining momentum

Alicia made exciting headway in giving ovarian cancer patients a voice at all levels of Welsh government. Quite literally...two of our Voices met with 15 Assembly Members during an awareness event hosted by Hannah Blythyn AM in the Senedd. Alicia also raised the topic of genetic testing with the Cabinet Secretary for Health and created new partnerships with local councils through ovarian cancer training sessions. It's fair to say she's put ovarian cancer firmly on the political agenda.

Walk In Her Name

Wales is home to a fantastic community of OCA supporters. One of our most active Voices, Alison Woolcock, made her mark this OCAM and organised Wales' largest Walk In Her Name in memory of her sister, Lesley. The walk was attended by more than 200 people – including Hannah Blythyn AM – and raised £3,000 to help fund much needed research.

We can't wait to see what Alicia and the ever-growing network of campaigners will accomplish next!

3

Training the professionals

Ovarian cancer is a rare disease and symptoms are easily missed by women and their doctors. With no national screening programme, it's vital that healthcare professionals can quickly recognise the disease's warning signs. That's why we partner with healthcare professionals at every level, to ensure they can confidently manage any ovarian cancer cases they encounter.

Providing information

We launched a brand new ovarian cancer education pack for GPs and other healthcare professionals at the Royal College of General Practitioners conference in October. The pack contains a range of information including:

- NICE Guidelines on hereditary ovarian cancer
- A GP guide to referring patients for genetic testing
- Symptoms information and diaries

750 GPs have already received these packs – that's 750 GPs who are more informed and better prepared to spot ovarian cancer.

Partnering with the Royal College of Nurses

Ovarian Cancer Action was thrilled to be part of this year's Royal College of Nursing Midlands educational programme. Our Cancer Prevention Officer Jo Stanford ran local learning events on BRCA and ovarian cancer across six West Midlands branches and was joined by Voices during the College's health awareness week to train more of their staff in England and Scotland. Everyone involved was keen to learn about hereditary ovarian cancer and 100% of the participants said they would recommend the training to their colleagues.

Raising awareness with GPs

Building on the success of last year, Health Projects Manager Ross Little ran a series of GP training sessions throughout 2017/18. The sessions covered ovarian cancer presentation and explored the best approach to making that all-important early diagnosis. We've reached a total of 2,000 GPs through training sessions, events and awareness materials.

4

New director of the Ovarian Cancer Action Research Centre

In November we were delighted to announce the appointment of Professor Iain McNeish as the new Director of the Ovarian Cancer Action Research Centre (OCARC). Iain is an internationally renowned scientist who brings 25 years of scientific and clinical expertise to the role.



PROFESSOR IAIN MCNEISH

We've had the privilege of collaborating with Iain for ten years on the translational research study BriTROC, and we are excited to see him take the lead at the Research Centre.

OCARC gained an international reputation for excellence in ovarian cancer research under the guidance of former Director, Hani Gabra. Iain is keen to build on the hard work and success of the last decade. By exploring new areas of research that offer fresh insights into treatment, Iain hopes to position the Research Centre at the forefront of the global effort to cure ovarian cancer.

5

Corporate Partnerships

Partnership is crucial to our success and it's a real privilege to join forces with entrepreneurs and businesses across the UK in the fight against ovarian cancer. Our corporate partners share our determination to beat ovarian cancer and find innovative ways to champion our cause. This year we've celebrated partnerships, new and old.

Partnering with Pureology

We were delighted to announce a new partnership with Pureology. This leading L'Oréal haircare brand was created by celebrity stylist Jim Markham after a close friend was diagnosed with ovarian cancer. He saw how sensitive her skin was to products after treatment and developed a kinder alternative. Pureology has been a generous partner, designing a hair care gift box and making a donation to us for each sale throughout March. Together we've raised awareness by generating some fantastic press. This culminated in a double-page feature in *The Times* which told the story of our Voice Danielle Golding. We're thrilled to say that after the success of 2018's campaign, Pureology has committed to support us through a multi-year partnership.

Ten years with Paperchase

It's been ten years since Paperchase partnered with Ovarian Cancer Action – and what a decade it's been. Every year Paperchase design six Mother's Day cards with 25p per card sold donated to OCA. This year's sales have taken the total raised to almost £90,000! We celebrated our 10th anniversary with lots of social media posts, in-store advertising, plus Paperchase profiled OCA

researcher, Dr Mara Artibani, as part of their #FierceFemales campaign. Here's to ten more years!

The best in the business

At OCA we are always looking for fresh opportunities to expand and develop new corporate partnerships. In November 2017 we established the Ovarian Cancer Action Business Development Committee to do just that. Chaired by OCA Board member Dr Wayne Phillips, it comprises 13 individuals at the top of their game across a broad range of industries from law to advertising. Their combined expertise and connections will guide our corporate engagement strategy and forge new relationships within the business community. It's early days but there are promising partnerships on the horizon.



6

Women V Cancer Ride the Night

2017 was a record-breaking year for Women V Cancer's Ride the Night!

The annual cycling challenge sees thousands of women ride through the night to raise vital money for three women's charities – Ovarian Cancer Action, Jo's Cervical Cancer Trust and Breast Cancer Care.

This year, 3,000 women unleashed some serious pedal power and cycled 100km through the twilight streets of London, all to create a better future for women facing cancer.



Together these women raised more than £1.5 million – an amazing achievement!

Ovarian Cancer Action is incredibly proud to be part of Women V Cancer. Not only is this coalition an important source of income for us, but the friendship, camaraderie and determination of everyone involved never fails to inspire us.



7

The Ovarian Cancer Action Development Appeal

We know the best way to beat ovarian cancer is to invest in research that challenges the disease from all sides.

Prevention, early detection, personalised treatment and excellence in surgical practice are the focus of an exciting new campaign we launched in autumn 2017: the Ovarian Cancer Action Development Appeal. The Development Appeal is an ambitious six-year appeal that unites scientists, clinicians and philanthropists into a partnership whose mission is to fund research that will save lives.

We were thrilled to launch Phase I at Number 11 Downing Street. A mix of corporate partners, cancer charity representatives, major donors, and Voices attended a special drinks reception to hear all about the campaign's vision.

Phase I: University of Oxford

Our ambition for Phase I is to make a further investment in Professor Ahmed Ahmed's laboratory at Oxford's Weatherall Institute of Molecular Medicine.

Professor Ahmed's work has two main aims: to detect ovarian cancer early and to prevent recurrence. His talented team of researchers have already made significant discoveries that have the potential to

transform how we treat and detect the disease. Now we must translate this potential into tangible solutions that stop women dying of ovarian cancer.

Phases II and III: The Ovarian Cancer Action Research Centre and beyond

Phases II and III aim to build a £4 million investment fund devoted to the next generation of scientific innovators at the Ovarian Cancer Action Research Centre, Imperial College, and throughout the rest of the UK. These scientists will tackle the big questions in ovarian cancer research such as why does the disease develop? How can we achieve excellent surgical outcomes? How do we overcome chemo-resistance? We will answer these questions by bringing together some of the best, most ambitious minds in science and business.

8

Community fundraising

Ovarian Cancer Action is incredibly proud to have such a dedicated community of fundraisers who make the work we do possible. They never fail to surprise and inspire us. Every year our supporters find new and inventive ways to raise money in their communities and this year was no exception. Here are some stand out moments from the last 12 months.

Festival fun

Dynamic fundraising pair and long term friends, Sue Richardson and Ann Martinelli, organised their community's very own indoor music festival to raise money for OCA. Lodgefest brought together local musicians and performers who entertained the festival-goers and



collected donations. The festival raised £6,292, taking Sue and Ann's overall fundraising total above £40,000!

A rare breed

July marked the start of a very special and heartfelt fundraising project created by Llansantffraid farmer Mr Emyr Wigley. Mr Wigley lost his wife, Evelyn, to ovarian cancer in October 2015. To help combat the disease and pay tribute to the many years they enjoyed together he decided to rear British Blues, a rare herd of cattle the couple kept together. Half of the money raised from the herd's eventual auction will fund research at the Ovarian Cancer Action Research Centre.

Business sense

Our Patron, Lord Digby Jones, has put his business expertise to use when raising money for Ovarian Cancer Action. From every sale of his most recent book, *Fixing Business*, he kindly donates to several charities. Book sales so far have raised more than £16,000 for us alone!

9

Risk and prevention research grants

In January, research kicked off at the Ovarian Cancer Action Research Centre into the genetic and lifestyle factors that increase a woman's chance of developing ovarian cancer. We awarded £70,624 to Dr James Flanagan and Dr Jonathan Krell for the first year of this research with the aim of giving women at high-risk a potentially life-saving head start against the disease.

Epigenetics and ovarian cancer risk

Research into epigenetics looks at changes in gene activity brought about by a range of lifestyle and environmental factors. It's an important area of study as epigenetic changes affect how the cells in our body read genes and can lead them to behave in a way that elevates our risk of developing cancer. Dr Flanagan hopes to uncover how epigenetic changes increase ovarian cancer risk in order to prevent it from developing in the first place. His research will investigate how BMI and the age at which a woman has her first period disrupt gene activity and makes her susceptible to the disease.

Genetic risk screening

Dr Jonathan Krell is assessing how feasible it would be to implement a new genetic testing model that identifies and supports families at risk of ovarian cancer. By exploring women's attitudes towards risk, technology, and access to cancer services, he hopes to improve current genetic testing services. Key questions include attitudes towards general population screening, the challenges and barriers to implementing risk screening, and how to improve current NHS guidelines for accessing BRCA testing.

funding life-saving research

symptom awareness

Stop Ovarian Cancer

#ActingonBRCA

10

OCA CHAIR, ALLYSON KAYE, AND RESEARCH CENTRE DIRECTOR, PROF. IAIN MCNEISH

Acting on BRCA

Genetic testing is one of our strongest weapons in the fight against ovarian cancer. Around 15% of ovarian cancer cases are caused by a BRCA gene mutation. This information can form the basis of a personalised cancer treatment and prevention strategy that could save 1,000 women's lives each year in the UK.

Our cancer prevention strategy

Ovarian Cancer Action has campaigned since 2013 for genetic testing to be used as an effective cancer prevention tool. The Government had made headway in improving access to genetic testing in the last two years. However, we knew from our supporters that more must be done to ensure families are offered the testing, information and support they were entitled to.

In October 2017 we took our campaign to Westminster and launched a new policy paper: *Acting on BRCA: Breaking down barriers to save lives*. The report presents what genetic testing looks like in the UK today. It examines the current challenges facing at-risk patients and their families, and makes 24 recommendations to improve services.

Who did we ask?

The report was based upon extensive research carried out by our team across 2017. We ran a genetic testing survey that was open to anyone who had an experience of trying to get a genetic test, had a cancer diagnosis or already knew they had a genetic mutation.

We also visited clinics, spoke with geneticists, and performed a literature review to build a picture of genetic services around country.

What did we find?

We were encouraged to see cases of best practice and hear from many patients who received excellent care throughout their BRCA journey. However, we also found regional variation in the provision and quality of services. Shockingly 29% of ovarian cancer patients were not offered testing despite NHS Guidelines. People across the country are still facing barriers to access testing and as a result women are developing ovarian cancer that could, and should, be prevented.

What's next?

Acting on BRCA makes a series of recommendations that include:

- The NHS must reach out to women diagnosed with ovarian cancer before 2015 to inform them of their eligibility for BRCA testing
- Lower testing eligibility threshold from 10% to 5%
- Patients should receive tailored emotional and psychological counselling as part of the genetic counselling process

Ovarian Cancer Action calls on the Government to implement these recommendations. We will continue to inform, to campaign, to act on BRCA and stop women dying before their time.

2017-2018

The year in numbers.

Scientists, fundraisers, and campaigners from all corners of the UK have been working non-stop to create a better future for women facing ovarian cancer. We are hugely proud of everything that we have accomplished together this year.

Fundraising

OCA fundraisers are a creative bunch, and this year they've pulled out all the stops to raise money through a range of community events and challenges. All in all they've...



Walked **4,232** miles



Run **3,490** miles



Peddled **235,636** miles – or more than nine times around the globe

Raised a whopping

£1,855,638

Campaigning

We've had conversations with 33 MPs and more than 14 Welsh Assembly Members to tackle urgent issues facing ovarian cancer patients. 531 men and women took part in our survey on genetic testing services. As a result we made 24 governmental recommendations across seven priority areas that could prevent 1,000 hereditary cancer cases each year.



Spreading the word



596,771

Our website was visited **596,771** times and our symptoms page had **127,788** views

4


We appeared in the media **1,090** times across all **4** nations

Our brand new About Us film was watched **15,285** times during Ovarian Cancer Awareness Month



Revenue

For every pound we spent...



Our community fundraisers have hosted an indoor festival, organised a Neil Diamond Tribute Evening, and thrown a Murder Mystery Night. They trekked through the Sahara Desert, climbed the Great Wall of China, and even drove 800 miles over the snow-capped Pyrenees in an old Volvo.



Thrown **1,047,000** punches in 25 boxing tournaments

Funding research

11

It's been 11 years since we founded Europe's first dedicated ovarian cancer research centre.

60

It's home to more than **60** scientists



£702,776

We spent £702,776 on ground-breaking research at the Ovarian Cancer Action Research Centre this year

Raising awareness

We distributed **57,472** awareness materials, including **27,602** symptoms diaries and **302** of our new 'Talking Ovaries' packs.



We reached **750** GPs with awareness packs & **90,000** patients with symptoms information in OCAM



118

We held **118** awareness events around the UK. Including **18** sessions with healthcare professionals and **6** with the Royal College of Nursing

5,664

We spoke to **5,664** people throughout the country. We had conversations with **1,219** healthcare professionals



Climbed **5** mountain peaks

Sky dived **9** times



Our structure, governance and management

Legal entity

Ovarian Cancer Action is a company limited by guarantee registered as a Company in England and Wales on 24 March 2005, and as a registered Charity in England and Wales on 27 May 2005. On 11 October 2012 the Charitable Company registered as a Scottish Charity at the office of the Scottish Charity Regulator. Its governing document is the Memorandum and Articles of Association.

Organisational structure

Ovarian Cancer Action is governed by a Board of Directors whose responsibilities include setting the strategic direction and goals of the Charity and providing effective governance. The Board meets four times a year. The Chief Executive is supported by a small team of staff, with a fulltime equivalent of 16 employees.

Role and contribution of volunteers

Nicholas Kaye FCA of AEL Partners LLP provides financial assistance on a pro bono basis. Ovarian Cancer Action is indebted to all those supporters who play a vital role in raising awareness of ovarian cancer in their communities, in the local and national media, and by raising funds for our work.

Appointment, induction and training of Directors

New Directors are appointed by the Board of Directors. All Directors must be members of Ovarian Cancer Action. Each new Director attends an induction session with the Chief Executive to confirm the role, responsibilities and expectations of Directors and highlight current governance and strategic issues. The session includes an overall view of the history of the organisation, current activities and future plans. New Directors are given internal training on the charitable activities of the organisation. Trustees are informed of relevant external training opportunities provided by organisations such as New Philanthropy Capital.

Grant-making policies

Ovarian Cancer Action invites applications for research funding from within and outside the Ovarian Cancer Action Research Centre. All grant applications are subject to rigorous peer review by the Scientific Advisory Board (SAB), which is an international, independent group of ovarian cancer research specialists chaired by Dr. Robert C. Bast Jr, Vice-President of Translational Medicine at the University of Texas MD Anderson Cancer Center.

Relationships with other charities

The Board of Directors actively seeks to collaborate with other charities where this will accelerate improvements in survival. Ovarian Cancer Action played a leading role in the establishment of Ovarian Cancer Awareness Month (OCAM) in the UK. Membership is held at Cancer 52, The Cancer Campaigning Group, the Association of Medical Research Charities (AMRC) and the Fundraising Standard Board. Ovarian Cancer Action has partnered with male cancer charity Orchid and The Robin Cancer Trust for future fundraising opportunities.

Risk management

The Board of Directors monitors the principal business and control risks to the charity and has completed a formal risk assessment. The principal risks to the charity include ensuring GDPR compliance and political uncertainty undermining the research environment in the UK. Plans to manage these risks are in place, including a new GDPR compliant database and Data Protection Officer, and working closely with the AMRC to monitor the possible impact of Brexit on our research.

Directors

The Board of Directors during the year and at the date of signing this report are listed on page 25, as are the company and charity numbers of Ovarian Cancer Action.

Financial Review

Financial review

The Directors report that the charity's incoming resources amounted to £1,855,638 a decrease from £2,072,195 in the previous year.

The Directors would like to thank all those volunteers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity in increasing numbers over the past year and upon whom we are dependent.

Income includes legacies of £142,915 (2017 - £508,947).

Total expenditure on charitable activities (research, awareness raising and giving a voice) and expenditure on raising funds amounted to £1,305,964 (2017 - £1,391,522) and £465,163 (2017 - £504,924) respectively. The Directors were delighted to be able to make additional research grants totalling £611,817 to fund work at the Ovarian Cancer Action Research Centre.

As a result of these activities, the charity has a surplus of £84,511 (2017 - £175,749).

Principal Funding Sources

A detailed breakdown of funding sources is given in Note 3 to the Financial Statements.

Reserves Policy

In accordance with Charity Commission guidance, free reserves are uncommitted reserves freely available which exclude restricted and designated funds and amounts invested in tangible fixed assets. Designated funds arise when the Directors set aside unrestricted funds for specific purposes.

Restricted funds arise when conditions are imposed by the donor, or by the specific terms of appeal, and can only be spent on the activities specified.

Ovarian Cancer Action relies almost entirely on voluntary income, which is subject to fluctuation. In order to ensure the continuance of the charity's day-to-day activities, the Directors have established a policy to hold free reserves equivalent to at least six months' expenditure excluding grants and expenditure from restricted funds planned for the year ahead.

At 31 March 2018 the Charity held total reserves of £2,184,479 (2017 - £2,099,968). These were split into restricted, designated and general funds.

At 31 March 2018, restricted funds amounted to £449,935 (2017 - £252,473). At 31 March 2018, designated funds amounted to £1,485,000 (2017 - £1,485,000); these were funds set aside to fund future research expenditure. The amount of the general fund available as a reserve against fluctuating income, at 31 March 2018, was £249,544 (2017 - £362,494). This amounted to approximately six months unrestricted non grant expenditure and thus complied with the reserves policy established by the Board."

The breakdown of the reserves between restricted, designated and general funds is shown in Note 14 to the Financial Statements.

Statement of directors' responsibilities

The trustees (who are also directors of Ovarian Cancer Action for the purposes of company law) are responsible for preparing the Directors' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the directors are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Signed on behalf of the Board



Dr Wayne Phillips, Chair
Chair, Board of Directors
Date: 21st November 2018

Reference and administrative details

Ovarian Cancer Action

A company limited by guarantee
Registered in England and Wales
5403443

Registered charity number
1109743 (England and Wales)
Registered charity number SC
043478 (Scotland)

Registered office

8-12 Camden High Street
London, NW1 0JH

Auditors

Kingston Smith
Devonshire House
60 Goswell Road
London, EC1M 7AD

Legal Advisors

Squire Patton Boggs (UK) LLP
7 Devonshire Square
London, EC2M 4YH

Accountant and Honorary Treasurer

Nicholas Kaye, FCA
AEL Markhams Ltd
201 Haverstock Hill
London, NW3 4QG

Bankers

National Westminster Bank PLC
1-4 Berkeley Square House
Berkeley Square
London, W1A 1SN

Coutts & Co
440 Strand
London, WC2R 0QS

Directors

Allyson Kaye MBE
(Chair, resigned 16th July 2018)
Nathalie Burdet
John Harris CBE
(resigned 15 March 2018)
Richard Hunt
(appointed on 9 January 2018)
Jenny Knott
Martin Paisner CBE
Dr Wayne Phillips
(Chair, appointed 16th July 2018)
Emma Scott
Lord Turnberg
(resigned on 18 September 2017)
Jane Wolfson
Professor Sir Nick Wright

Honorary Patrons

The Hon. Nigel Havers
Lord Jones of Birmingham
Gwyneth Strong

Honorary President of Ovarian Cancer Action

Dr. Robert C. Bast Jr

Chief Executive

Katherine Taylor

Scientific Advisory Board

Dr Robert C. Bast, Jr.
Dr Jonathan Berek
Dr Michael Bookman
Professor Vincenzo Cerundolo
Professor Barbara Goff
Professor Adrian Harris
Professor Ian Hart
Dr Ernst Lengyel
Dr Elise Kohn
Dr Karen Lu
Professor David Neal
Professor Kenneth Nephew
Professor Gordon Rustin
Dr Michael Seiden
Professor Anil Sood

Independent auditors' report to the trustees and members of Ovarian Cancer Action

Opinion

We have audited the financial statements of Ovarian Cancer Action for the year ended 31 March 2018 which comprise Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Ireland' (United Kingdom Generally Accepted the UK and Ireland').

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2018 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended) and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Independent auditors' report to the trustees and members of Ovarian Cancer Action (continued)

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 or the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a Strategic Report.

Independent auditors' report to the trustees and members of Ovarian Cancer Action (continued)

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 21, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Independent auditors' report to the trustees and members of Ovarian Cancer Action (continued)

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and to the charitable company's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report addressed to them and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, and the charity's trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Andrew Stickland (Senior Statutory auditor)
Date: 21st November 2018

for and on behalf of Kingston Smith LLP,
Statutory Auditor
Devonshire House
60 Goswell Road
London, EC1M 7AD

Kingston Smith LLP

Statement of Financial Activities (including Income and Expenditure account) for the year ended 31 March 2018

	Notes	Unrestricted Funds £	Restricted Funds £	Total 2018 £	Total 2017 £
Income					
Donations and legacies	3	1,529,424	245,138	1,774,562	2,065,379
Other income		79,398	-	79,398	-
Investment income		1,678	-	1,678	6,816
Total income		1,610,500	245,138	1,855,638	2,072,195
Expenditure					
Expenditure on raising funds	4	465,163	-	465,163	504,924
Expenditure on charitable activities	5	911,847	394,117	1,305,964	1,391,522
Total expenditure		1,377,010	394,117	1,771,127	1,896,446
Net income/(expenditure)		233,490	(148,979)	84,511	175,749
Transfer between funds		(346,441)	(346,441)	-	-
Net movement in funds		(112,951)	197,462	84,511	175,749
Total funds at 1 April 2017		1,847,495	252,473	2,099,968	1,924,219
Total funds at 31 March 2018	14	1,734,544	449,935	2,184,479	2,099,968

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The accompanying notes form part of these financial statements.

Balance Sheet as at 31 March 2018

	Notes	2018 £	2017 £
Fixed Assets			
Tangible assets	9	-	1
Current assets			
Debtors	10	645,244	377,483
Cash and short term deposits		2,753,211	3,093,175
		<u>3,398,455</u>	<u>3,470,658</u>
Liabilities			
Creditors: amounts falling due within one year	11	<u>1,213,976</u>	<u>1,370,691</u>
Net current assets		2,184,479	2,099,967
Net Assets		2,184,479	2,099,968
Represented by:			
Unrestricted funds	14(i)		
General fund		249,544	362,495
Designated funds		<u>1,485,000</u>	<u>1,485,000</u>
		1,734,544	1,847,495
Restricted funds	14(ii)	449,935	252,473
		<u>2,184,479</u>	<u>2,099,968</u>

Approved by the Board of Directors and authorised for issue on 21st November 2018



Dr Wayne Phillips

Chairman of the Board

Company Registration No. 5403443

The accompanying notes form part of these financial statements.

Statement of Cash Flows for year ended 31 March 2018

	Notes	2018		2017	
		£	£	£	£
Cash flows from operating activities					
Cash flows provided/(used in) by operating activities	16		(341,643)		647,194
Cash flows from investing activities					
Disposal of fixed assets		1		-	
Interest received		1,678		6,816	
Net cash provided by investing activities			1,679		6,816
Net increase/(decrease) in cash and cash equivalents of the financial year			(339,964)		654,010
Cash and cash equivalents at the beginning of the financial year			3,093,175		2,439,165
Cash and cash equivalents at the end of the financial year			2,753,211		3,093,175

Notes to the Financial Statements for the year ended 31 March 2018

1.1 Basis of accounting

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2016.

The financial statements are prepared in sterling which is the functional currency of the Charity.

The Charitable company meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The Directors consider that there are no material uncertainties about the charitable company's ability to continue as a going concern.

1.2 Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donations are recognised on receipt. Donations from fundraising ventures are shown gross, with the associated costs included in fundraising costs. Other income is accounted for on a receivable basis.

Income from government and other grants is recognised when the charity has entitlement to the funds, and any performance conditions attached to the grants have been met.

Legacies are recognised at the earlier of the date on which either the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executors to the charity that a distribution will be made or when a distribution is received from the estate. Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank

Notes to the Financial Statements for the year ended 31 March 2018 (Cont)

1.3 Fund accounting

The following funds are held by the charity:

- Unrestricted general funds - these are funds which can be used in accordance with the charitable objects at the discretion of the Board of Directors.
- Designated funds - these are funds set aside by the Board of Directors out of unrestricted general funds for specific future purposes or projects.
- Restricted funds - these are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

1.4 Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs associated with attracting voluntary income and the costs associated with fundraising purposes.
- Expenditure on charitable activities comprises those costs incurred by the charity in the delivery of its activities and services. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support it.
- Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is recognised once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the one year or multi-year grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Directors.

Value added tax is not recoverable and as such is included in the relevant costs in the Statement of Financial Activities.

1.5 Costs allocation

Costs are allocated between the expenditure categories of the Statement of Financial Activities on a basis designed to reflect the use of the resource. Costs other than support costs relating to a particular activity are allocated directly. Support costs (staff costs) are allocated to the expense categories according to the role of the individual; the apportionment is disclosed in note 6.

Governance costs comprise all costs involving public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and an apportionment of staff costs. Governance costs are allocated in proportion to expenditure on raising funds and expenditure on charitable activities.

1.6 Operating leases

Rentals payable under operating leases are charged to the Statement of Financial Activities as incurred.

1.7 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation is provided on a straight line basis at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment	20%
------------------	-----

Fixed assets below £500 are expensed directly to the SOFA.

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

1.8 Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.9 Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity from the date of opening the deposit.

1.10 Creditors

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

1.11 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments which include trade and other receivables, trade and other payables and cash and bank balances. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.12 Pensions

Employees of the charity are entitled to join a defined contribution 'money purchase' scheme unless they have exercised their right to opt out of the scheme membership. The money purchase plan is managed by The People's Pension and the plan invests contributions made by the employee and employer in an investment fund to build up over the term of the plan. The pension fund is then converted into a pension upon the employee's normal retirement age which is defined as when they are eligible for a state pension. The charity has no liability beyond making its contributions and paying across the deductions for the employee's contributions.

1.13 Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the average rate for the month in which the transaction occurred. All differences are taken to the Statement of Financial Activities.

1.14 Key estimates and judgements

In the application of the company's accounting policies, the Council is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

In the opinion of the Trustees, there are no estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities.

2 Legal status of the charity

The charity is a company limited by guarantee and has no share capital. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the charity.

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

3 Donations and legacies

	2018		2017	
	£	£	£	£
	General	Restricted	Total	Total
Charitable trusts	302,400	157,500	302,400	48,683
Third party fundraising	165,381	-	165,381	149,447
Legacies	142,915	-	142,915	508,947
In memoriam	54,141	3,502	54,141	85,158
Challenge and running events	702,560	81,400	702,560	794,652
Other donations	407,165	2,736	407,165	478,492
	1,774,562	245,138	1,774,562	2,065,379

Income from donations and legacies was £1,774,562 (2017 - £2,065,379) of which £1,529,339 (2017 - £2,041,289) was unrestricted and £245,223 (2017 - £24,090) was restricted.

4 Expenditure on raising funds

	2018	2017
	£	£
Staff costs (see note 8)	286,697	242,309
Challenge and running events	86,417	155,817
Other	38,959	57,056
	412,073	455,181
Support costs (see note 6)	53,090	49,743
	465,163	504,924

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

5 Charitable Activities

	Staff Costs	Direct	Support Costs	Total 2018
	£	£	£	£
	(see note 8)		(see note 6)	
Grants payable				
Ovarian Cancer Action Research Centre	-	611,817	78,825	690,642
Imperial College/Hammersmith Hospital	-	90,959	11,719	102,678
Research grants overspend (underspend)	-	702,776	90,544	793,320
Other Charitable Activities				
Research Management	58,439	51,925	14,219	124,583
Awareness Activities	158,424	116,256	35,388	310,068
Giving a Voice Activities	48,429	856	6,350	55,635
	265,292	169,037	55,957	490,286
Governance costs (see note 7)		19,806	2,552	22,358
	265,292	891,619	149,053	1,305,964

	Staff Costs	Direct	Support Costs	Total 2017
	£	£	£	£
	(see note 8)		(see note 6)	
Grants payable				
Ovarian Cancer Action Research Centre	-	960,000	104,909	1,064,909
Imperial College/Hammersmith Hospital	-	(69,674)	(7,614)	(77,288)
Research grants overpend (underspend)	-	890,326	97,295	987,621
Other Charitable Activities				
Research Management	53,283	14,047	7,358	74,688
Awareness Activities	129,033	111,155	26,248	266,436
Giving a Voice Activities	35,884	935	4,024	40,843
	218,201	126,136	37,630	381,967
Governance costs (see note 7)		19,773	2,161	21,934
	218,201	1,036,235	137,086	1,391,522

Expenditure on charitable activities was £1,305,964 (2017 - £1,391,522) of which £913,459 (2017 - £1,105,905) was unrestricted and £392,505 (2017 - £285,617) was restricted.

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

5 Charitable Activities (continued)

	Total 2018	Total 2017
	£	£
Reconciliation of grants payable		
Commitments at 1 April 2017	1,242,561	1,033,337
Commitments made in the year	611,817	960,000
Research grants overspend (underspend)	90,959	(69,674)
Grants paid during the year	(818,484)	(681,102)
Commitments at 31 March 2018	1,126,853	1,242,561

Commitments at 31 March 2018 and 31 March 2017 are payable within 1 year (note 11).

6 Support Costs Allocation

	2018	2017
	£	£
Staff costs (see note 8)	54,522	47,752
Other staff costs	18,987	10,203
Travel	3,293	5,581
Rent	77,843	73,366
IT	10,989	10,180
Consultancy fees	7,864	13,141
Office costs	28,645	26,605
	202,143	202,143

7 Governance costs

	2018	2017
	£	£
Auditor's fees	9,450	11,400
Auditor's other fees - accountancy	10,356	7,800
Support costs (see note 6)	2,552	2,161
	22,358	21,361

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

8 Directors and employee information

No Director received any remuneration from the Charity (2017 - Nil). One staff member was paid in the £70,000 - £80,000 band (2017 - 1 £60,000 to £70,000). One director was reimbursed £388 travel and subsistence (2017 - £314 travel and subsistence)

The number of persons employed by the Charity during the year was 17 (2017 - 15).

	2018	2017
	£	£
Amounts paid to employees of the Charity during the year:		
Salaries and wages	547,026	459,314
Pension costs (see note 13)	7,591	7,594
Social security costs	51,893	39,461
	606,510	506,369

The Charity considers its key management personnel comprise the Directors, the Chief Executive Officer and the senior management team including the Public Affairs and Operation Manager, Senior Fundraising Manager, Research Fundraising Manager and Head of Communications. The total employee benefits of the key management personnel were £241,505 (2017 - £269,928).

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

9 Tangible fixed Assets

	Office Equipment
Cost	
At 1 April 2017	34,206
Disposals	(34,206)
At 31 March 2018	-
Depreciation	
At 1 April 2017	34,205
Disposals	(34,205)
At 31 March 2018	-
Net book values	
At 31 March 2018	-
At 31 March 2017	1

10 Debtors

	2018 £	2017 £
Other Debtors	624,315	355,967
Prepayments	20,929	21,516
	645,244	377,483

Other debtors includes amounts totalling £168,627 (2017 - £nil) receivable after more than one year

11 Creditors

	2018 £	2017 £
amounts falling due within one year		
Trade creditors	54,981	90,779
Social security and other taxes	15,668	16,890
Grants not yet paid	1,126,853	1,242,561
Accruals	16,474	20,461
	1,213,976	1,370,691

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

12 Financial Commitments

At 31 March 2017 the charity was committed to making the following payments under a non-cancellable operating lease in respect of land and buildings as follows:

	Other 2018	2017	Land & Buildings 2018 £	2017 £
Operating lease which expires:				
Within one year	1,637	1,637	57,500	57,944
Between 2 and 5 years	1,405	3,402	84,123	-
	3,042	5,039	141,623	57,944

13 Pension Costs

The charity contributes to a defined contribution pension scheme.

The assets of the scheme are held separately from those of the charity in independently administered funds.

The pension cost charge representing contributions payable by the charity to the funds amounted to £7,591 (2017 - £7,594). As at 31 March 2018 £nil (2017 - £2,638) remained unpaid.

14 Funds

(i) Unrestricted funds

Analysis of movements in unrestricted funds

	General fund £	Designated funds £	Total £
At 1 April 2017	362,495	1,485,000	1,847,495
Net income for year	233,490	-	233,490
	595,985	1,485,000	2,080,985
Transfer	(346,441)	-	(346,441)
At 31 March 2018	249,544	1,485,000	1,734,544

Designated funds are in respect of planned research work at the Ovarian Cancer Action Research Centre, Imperial College and University of Oxford.

Analysis of movements in unrestricted funds - previous year

	General fund £	Designated funds £	Total £
At 1 April 2016	200,219	1,210,000	1,410,219
Net income for year	437,276	-	437,276
	637,495	1,210,000	1,847,495
Transfer	(275,000)	275,000	-
At 31 March 2017	362,495	1,485,000	1,847,495

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

(ii) Restricted funds

Analysis of movements in restricted funds

	Movements in Funds				As at 31.3.2018 £
	As at 1.4.2017 £	Incoming £	Outgoing £	Transfer between funds £	
Ovarian Cancer Research Research Centre, Imperial College		26,208	(175,898)	149,690	-
Tampon Tax Fund (see below)	-	-	(30,578)	30,578	-
Other	-	-	(166,173)	166,173	-
University of Oxford	200,000	216,935	-	-	416,935
Public/regional Awareness					
Tampon Tax Fund (see below)	40,491	-	(8,498)	-	31,993
Other	11,982	1,995	(12,970)	-	1,007
	252,473	245,138	(394,117)	346,441	449,935

Analysis of movements in restricted funds -previous year

	Movements in Funds				As at 31.3.2017 £
	As at 1.4.2016 £	Incoming £	Outgoing £	Transfer between funds £	
Ovarian Cancer Research Research Centre, Imperial College					
Tampon Tax Fund (see below)	250,000	-	(250,000)	-	-
Other	-	10,050	(10,050)	-	-
University of Oxford	200,000	-	-	-	200,000
Public/regional Awareness					
Tampon Tax Fund (see below)	50,000	-	(9,509)	-	40,491
Other	14,000	14,040	(16,058)	-	11,982
	514,000	24,090	(285,617)	-	252,473

Government Grants

In March 2016 a donation of £300,000 was granted from the Treasury, narrated as the Tampon Tax Fund above, to fund the Charity's cancer prevention strategy. This was largely utilised in the current year through public awareness raising carried out by a new Cancer Prevention Officer at the Charity and research at the Ovarian Cancer Action Research Centre.

Transfer between funds

The transfer between funds relates to the charity spending their unrestricted funds on the restricted projects.

Notes to the Financial Statements for the year ended 31 March 2018 (cont)

15 Analysis of net assets between funds

	Restricted	Unrestricted Funds		Total
	£	General £	Designated £	£
Fixed assets	-	-	-	-
Current assets less liabilities	252,473	447,006	1,485,000	2,184,479
	252,473	447,006	1,485,000	2,184,479

16 Cash generated from operations

	2018 £	2017 £
Net Movement in Funds for the Year	84,511	175,749
Adjustments for:		
Impairment and depreciation of fixed assets	-	-
Interest income	(1,678)	(6,816)
Movements in working capital:		
Decrease/(Increase) in debtors	(267,761)	247,251
Increase/(decrease) in creditors	(156,715)	231,010
Cash flows provided/(used in) by operating activities	(341,643)	647,194

17 Related party transactions

There have been no related party transactions in the year ended 31 March 2018 or in the year ended 31 March 2017.

Taking action together

Thank you

Beating ovarian cancer is not an easy task, but we are proud to say we are not fighting alone. Thank you to each and every one of you for supporting us, funding research, raising awareness and campaigning for change. Together we can, and will, change the future.

Special thanks to

Professor Ahmed Ahmed
Amy Allen
Minaxshi Amaneer
Suzie Aries
AR & V Investments
AstraZeneca
Edward Azouz and family
Robert Bast Jr
The estate of Barbara Bentley
The Benham Charitable Settlement
Solvej Biddle
Hannah Blythyn AM
Bob Bowyer
Boxercise Ltd
Buccleuch Property
Nathalie Burdet
Helen & John Burn
Eric Campus
Paula Cann
Howard Calvert
Gemma Carroll
Kirsty Chisholm
Ingrid Copperman
Claire & Alan Dalton
Judy & David Dangoor
Pascale & Jean-Francois Decaux
Linda Drew
Dollond Charitable Trust
Doris Field Charitable Trust
Dorset Foundation
Dream Challenges
Gemma & James Dunitz
eBay
Tony Eisen
The Emly family and friends
Dr Angela George
Danielle Golding
Joanna Gosling

The Grace Trust
Kim & Andy Gray
Greendale Foundation
Ewa Gruszecka-Grant
The Forte Charitable Trust
John Hackney
Darren Halmshaw
Susan Hammond
Sharon Hodgson MP
Paramjit Hunjan
Professor Richard Hunt
Katie Irwin
Isle of Man Anti-Cancer Association
Vicky Jacobs
The James Tudor Foundation
Stuart James
Lord Digby Jones
Sharon Jones
Allyson Kaye MBE
Nic Kaye
Jenny Knott
Dr Jonathan Krell
Rosie Lapsley
The estate of Paula Larratt
Law Society of Scotland
Trevor & Donna Leigh
Henry Lennard
Anita Leslau
Sara Le-Surf
The Lexus Foundation
Andy Grieff-Liggins
LifeArc
John Lynch
The Maley family and friends
Ann Martinelli
Abi McAdam
McCann Health
Professor Iain McNeish



Laura Moses
Aimi Munro
Fiona Murphy
Daniel Murray
NEXT
N J D Charitable Trust
Nursing Times
Christina Pacitti
Martin Paisner CBE
Paperchase
Dr Wayne Phillips
Rebecca Platt
The Pleasant Foundation
Bev Poulton
Pureology
Caroline Raphael
Raffingers Foundation
Red Rocks Nusing Home Ltd
Sue Richardson
Rosetrees Trust
Adele Sewell
Emma Scott
The Sobell Foundation
Gwyneth Strong
Deborah Tanner
Katherine Taylor
Lord Turnberg
Emmanuelle Whale
The Whitchurch Community Group
Mr Emyr Wigley
Florence Wilks
Sir Donald & Lady Edna Wilson Charitable Trust
Jane Wolfson
Alison Woolcock
Professor Sir Nicholas Wright

A very special thank you to all of the Ovarian Cancer Action Voices, our incredible London Marathon Team, and every other person who has run, cycled, walked, boxed, trekked, hosted events and fundraised for us. Thank you for being part of #TeamOCA.



We are the UK's ovarian cancer research charity and our mission is to fund research that saves lives.

But we can't do it alone. Overcoming ovarian cancer is about working together. It's about joining forces and becoming greater than the sum of our parts.

From funding scientists on the front line, to mobilising millions of people across the UK to take action - we're driven by a vision of a world without ovarian cancer and a belief that we can create a better future. And it starts today, with you.

Join us. Fight with us. Act now.

CONTACT US